Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococcal central-line-associated bloodstream infections in a neonatal intensive care unit | Zendy

Ana C. Blanchard | Zendy; Élise Fortin | Zendy; Craig A. Laferrière | Zendy; Isabelle Goyer | Zendy; Ahmed Moussa | Zendy; Julie Autmizguine | Zendy; Caroline Quach | Zendy

Open Access

Comparative effectiveness of linezolid versus vancomycin as definitive antibiotic therapy for heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococcal central-line-associated bloodstream infections in a neonatal intensive care unit

Author(s) -

Ana C. Blanchard,

Élise Fortin,

Craig A. Laferrière,

Isabelle Goyer,

Ahmed Moussa,

Julie Autmizguine,

Caroline Quach

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx059

Subject(s) - linezolid , medicine , vancomycin , retrospective cohort study , neonatal intensive care unit , intensive care unit , intensive care , antibiotics , cohort , intensive care medicine , pediatrics , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics

Heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococci (hVICoNS) are emerging pathogens causing central-line-associated bloodstream infections (CLABSIs) in neonatal intensive care unit (NICU) patients. Given the burden of disease associated with CLABSI and the current lack of therapeutic guidelines, we aimed to compare the effectiveness of linezolid versus vancomycin used as the definitive antibiotic therapy for hVICoNS CLABSI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research